Zydus biopharma Arm Buys Global Proprietary Rights For Progeria Treatment

Sentynl Therapeutics Inc (Sentynl), a US-based biopharmaceutical organization entirely claimed by Ahmedabad-settled Zydus Lifesciences, as of late finished the procurement of worldwide exclusive rights for Zokinvy. Zokinvy is the first and only treatment for Progeria in children over the age of 12 that has been approved by the US Food and Drug Administration (FDA).

Progeria, which envelops Hutchinson-Gilford Progeria Syndrome (HGPS), and Processing-Deficient Progeroid Laminopathies (PDPL), are super uncommon, lethal, hereditary, untimely maturing sicknesses that speed up mortality in youthful patients.

After getting a USFDA endorsement in 2020, Zokinvy also received endorsements in the European Union Great Britain (2022) and Japan (January 2024). This development of pharmaceutical firm Zydus' portfolio incorporates meds for intriguing illnesses.

“This acquisition signifies an important milestone in expanding our portfolio of medicines for rare and orphan diseases, which can have devastating consequences if left untreated. We are dedicated to supporting patients in living healthier and more fulfilling lives,” stated a representative from Zydus.

“By adding Zokinvy to our portfolio of products, we aim to address the needs of rare disease patients, whose requirements are often unmet or disregarded,” commented Matt Heck, president & CEO of Sentynl.

Audrey Gordon, President and Executive Director of The Progeria Research Foundation (PRF) remarked, “Without Zokinvy therapy, children with Progeria succumb to the same heart disease that affects millions of normally aging adults, but at an average age of 14.5 years old. Zokinvy provides these beautiful children with longer, healthier lives.”